Anika Therapeutics (ANIK) Other Non-Current Assets (2010 - 2026)

Anika Therapeutics (ANIK) has reported Other Non-Current Assets for 17 consecutive years, with $3.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Assets fell 45.53% year-over-year to $3.0 million in Q2 2026; TTM through Jun 2026 was $3.0 million, a 45.53% decrease from a year earlier, with the FY2025 full-year figure at $4.0 million, down 28.68% from the prior year.
• Other Non-Current Assets was $3.0 million for Q2 2026 at Anika Therapeutics, down from $4.3 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $36.3 million in Q4 2023 and troughed at $3.0 million in Q2 2026.
• A 5-year average of $14.0 million and a median of $17.4 million in 2022 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets jumped 110.84% in 2023 and tumbled 84.42% in 2024, its largest moves.
• Over 5 years, Other Non-Current Assets stood at $17.2 million in 2022, then soared by 110.84% to $36.3 million in 2023, then plunged by 84.42% to $5.7 million in 2024, then fell by 28.68% to $4.0 million in 2025, then declined by 25.06% to $3.0 million in 2026.
• The last three Other Non-Current Assets figures came in at $3.0 million (Q2 2026), $4.3 million (Q1 2026), and $4.0 million (Q4 2025), per Business Quant data.